Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer

Kathleen N Moore; Sandro Pignata

doi:10.1136/ijgc-2018-000071

Citation Tools

other Versions

You are currently viewing an earlier version of this article (March 31, 2021).
View the most recent version of this article

Clinical Trial

Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Moore KN, Pignata S

Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer

International Journal of Gynecologic Cancer Published Online First: 10 January 2019. doi: 10.1136/ijgc-2018-000071

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password